Semaglutide
SURMOUNT-5
Novo Nordisk · Phase 3 · Completed · Enrollment 751
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| 15 mg or MTD - Tirzepatide | Obesity or overweight | 15 mg | 72 | n/r | n/r |
| 2.4 mg or MTD - Semaglutide | Obesity or overweight | 2.4 mg | 72 | n/r | n/r |